Archives




Blog Post | News, Science + Research

Clinical Trial Alert: ReveraGen BioPharma Seeks Participants for a Phase 2b DMD Study

Researchers at ReveraGen BioPharma are looking for ambulatory boys with Duchenne muscular dystrophy (DMD) to participate in a Phase 2b study. The goal of the study is to evaluate the…

Tags: Clinical Trial Alert, Clinical Trials, Drug Development


Blog Post | News, Science + Research

FDA Grants Breakthrough Therapy Designation to Amicus’ Experimental Therapy, AT-GAA, for Late-Onset Pompe Disease

On Feb. 25, Amicus Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation (BTD) to AT-GAA, Amicus’ investigational combination drug therapy ATB200/AT2221 for treating late-onset Pompe disease. The…

Tags: Clinical Trials, Drug Development, Research, Research Advances


Blog Post | News, Science + Research

Clinical Trial Alert: Amicus Therapeutics Seeks Participants for a Phase 3 Late-Onset Pompe Disease Study

Researchers at Amicus Therapeutics are looking for adults with late-onset Pompe disease (LOPD) to participate in a Phase 3 study. The goal of the study is to evaluate the safety…

Tags: Clinical Trial Alert, Clinical Trials, Drug Development, Research


Blog Post | News

In Their Shoes: 65 Years of IAFF’s Fight for MDA

In 1952 in South Boston, Charles Crowley was desperate for help. His two sons were living with Duchenne muscular dystrophy (DMD) and needed care. The family needed resources. Charles called…

Tags: Fill the Boot, Fundraising, Summer Camp


Blog Post | News, Science + Research

FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping

On Feb. 14, Sarepta Therapeutics announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) seeking approval under Priority Review for golodirsen (SRP-4053), its drug…

Tags: Clinical Trials, Drug Development, Exon Skipping, Gene Therapy, Research, Research Advances


Blog Post | News, Science + Research

CMTA and MDA Co-Fund Proof-of-Concept Study Using AAV Vector to Deliver Gene Replacement Therapy in X-linked Charcot-Marie-Tooth Disease

On Mar. 1, the Charcot-Marie-Tooth Association (CMTA) and the Muscular Dystrophy Association (MDA) announced that they have jointly awarded a research grant totaling $276,430 over three years to Kleopas Kleopa,…

Tags: Drug Development, Gene Therapy, Grants, Research


Blog Post | Personal Stories

Strengthened by Spinraza, Marley Robinson is Tackling College — and Planning for More

Feb. 28 is Rare Disease Day, when the collective rare disease community raises awareness of the conditions with which we live and advocates for access to new novel treatments like…

Tags: Ambassadors, College, Education, Young Adults


Blog Post | News, Science + Research

MDA Releases New DMD Fact Sheet During Duchenne Muscular Dystrophy Awareness Week

Feb. 13-18, as established by MDA’s colleagues at Parent Project Muscular Dystrophy (PPMD), is Duchenne Muscular Dystrophy Awareness Week, when we recognize both the individuals and families impacted by Duchenne…

Tags: Resources


Blog Post | News, Science + Research

Long-Term Results of Extension Study Validate Surgery as a Treatment for Myasthenia Gravis

Results of an extension study following an MDA-supported clinical trial showed that surgical removal of the thymus in patients with myasthenia gravis (MG) offered benefits for as long as five…

Tags: Clinical Trials, Research


Blog Post | News

Trexo Robotics Releases Trexo Home Walking Aid for Children

Joining a growing number of companies developing robotic devices for those living with mobility impairments, Ontario’s Trexo Robotics just launched the newest in its line of robotic walking aids specifically…

Tags: Innovation, Technology